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Abstract
Background: Extracorporeal membrane oxygenation (ECMO) has been recommended for the treatment of patients
with acute, potentially reversible, life-threatening respiratory failure which unresponsive to conventional therapy. But
it is unclear about how ECMO affects renal tissue.
Methods: Twenty-four piglets weighing 25 to 32 kg were used in this experiment. The piglets were randomly
allocated to 4 groups of 6 animals each: sham group (S group), control group (C group), VV-ECMO group (E group),
VV-ECMO combined with CRRT group (EC group). The piglets were sacrificed and the kidney tissue were harvest to
determine the levels of IL-1β, IL-6, TNF-α and NF-КB by using the ELISA and RT-PCR method, respectively.
Results: Compared with C group and S group, E group renal tissue IL-1β, IL-6, TNF-α and NF-КB expression
increased significantly, respectively (p < 0.01). Compared with E group, EC group showed renal tissue IL-1β, IL-6,
TNF-α and NF-КB expression decreased significantly, respectively (p < 0.05).
Conclusion: ECMO enables to inflammatory cytokines including IL-1β, IL-6, TNFα, NF-КB released significantly, renal
function impaired and immune homeostasis were to imbalance; ECMO combined with CRRT treatment can alleviate
levels of inflammatory cytokines, maintain immune homeostasis balance and thus ameliorate the ECMO-related
acute kidney injury(AKI).
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Background
Extracorporeal membrane oxygenation (ECMO) has
been recommended for the treatment of patients with
acute, potentially reversible, life-threatening respiratory
failure which unresponsive to conventional therapy
[1-3]. However, ECMO-related serious complications
often lead to treatment failure because of long-term
treatment support and more organs implicated. ECMO-
induced acute renal dysfunction is a heavy burden for
the society and a non-negligible problem [4,5]. Extracor-
poreal Life Support Organization (ELSO) Registry has
indicated incidence of ARF during ECMO is up to 34.7%
[6]. Nevertheless, the underlying mechanisms of acute
renal failure during ECMO support are still unclear. Sell
et al [7] have maintaned ECMO-induced acute renal
dysfunction is mainly ascribed to pre-hypoxia and renal
hypoperfusion. Gbadegesin et al [8] have suggested that
hemolysis is a common complication during ECMO
which may further impair renal function and delay renal
recovery. However, kelly et al [9] have reported activa-
tion of cytolines might play a critical role in the changes
of renal function. Continuous renal replacement therap-
ies (CRRT) present significant advantages in terms of
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well clinical tolerance from a hemodynamic condition
and blood purification. CRRT may provide effort to
maintain optimal fluid status in patients receiving
ECMO. It is an effective measure method in dealing with
acute renal failure during ECMO support. Previous stud-
ies indicated that CRRT had been found to remove the
inflammatory cytokines in both animal studies and clin-
ical researches. This study was designed to investigate
the expression of renal inflammatory cytokines by re-
ceiving concomitant ECMO and CRRT in the healthy
swine model so as to better apply the extracorporeal life
support technology for clinical patients.
Methods
Animals and groups
Twenty-four piglets weighing 25 to 32 kg were used
in this experiment. All animals were used and cared
followed “The Principles of Laboratory Animal Care”
by the National Society of Medical Research and with
the “Guide for the Care and Use of Laboratory Ani-
mals” (http://www.nap.edu/catalog/ 5140.html). This
study was approved by the Animal Care Committee of
Jingling Hospital.
The piglets were randomly allocated to 4 groups of 6 ani-
mals each: sham group (S group),control group (C group),
VV-ECMO group (E group), VV-ECMO combined with
CRRT group (EC group). The studies were done 24 hours.
Surgical procedure
Anesthesia was induced with intramuscular injection
of ketamine (20 mg/kg), diazepam (8 mg/kg), atropine
(0.1 mg/kg) and maintained with intravenous keta-
mine (10-20 mg/kg/hr) and diazepam (8 mg/kg/hr). A
22-gauge intravenous (IV) catheter was then placed in the
ear vein, and crystalloid fluid was administered at a rate of
7 to 10 mL/kg/h. After tracheotomy and an internal diam-
eter 6.0 cm tracheal tube placement, mechanical ventila-
tion was established, using volume-controlled mode with
FiO2 of 21% and a positive end-expiratory pressure set at
5 mmHg throughout the experimental period. Tidal vol-
umes were adjusted to 5-8 mL/kg. Respiratory rate was set
at 15/min.
A venous catheter was placed into right internal
jugular vein to administer Ringer’s lactate at a rate of
3 mL/kg/hr initially. The rate was increased to main-
tain the mean arterial pressure above 60 mmHg. The
groin was instrumented via cutting down with a fem-
oral arterial line for hemodynamic monitor and labora-
tory samples. A femoral venous line was placed for
administration of intravenous fluids and medication. At
the end of the experiment, the piglet was sacrificed
with Potassium Chloride (40 mL, 1 mol/L,i.v.). The
right kidney was removed rapidly and stored at -80°C
for subsequent analysis.
VV-ECMO proceduce
Before cannulation, each animal received bolus heparin
(150 U/kg), followed by a continuous infusing of heparin
to keep the activated clotting time (ACT) at 180 to 220 s
during the process of ECMO. Right internal jugular vein
was cannulated with a 17Fr Biomedicus arterial cannula
(Medtronic Perfusion Systems, Minneapolis, MN), which
was advanced into the right atrium. And another a 17 Fr
Biomedicus venous drainage cannula (Medtronic Perfu-
sion Systems, Minneapolis, MN) was inserted into right
femoral vein. Placement of these cannulae was con-
firmed by ultrasound.
ECMO circuit (Quadrox PLS,Maquet,Germany) was
primed with 500 ml Voluven and 200-300 ml Ringer’s
lactate. The VV-ECMO system consisted of a centrifugal
pump (Rotaflow Console, Maquet, Germany), and a heat
exchange (Heater-Cooler Unit HCU 30, Maquet,
Germany)maintaining temperature at 37°C. Sweep gas
was 100% oxygen at a flow rate equal to the blood flow
rate (1:1). Blood in circuit was drained from right fem-
oral vein and infused into internal jugular vein at the
rate of 50 ml/(kg.min).
CRRT setting
CRRT was performed in a pre-dilution mode using a
polysulfone membrane (1.4 m2 AV 600 s, ultraflux,
Germany) connected to a continuous blood pump (Baxter
BM 25, Baxter SAN Germany). Blood flow rate was set
at 160-180 mL/min. A lactate-buffered replacement fluid
(deploy Jingling prescription, china) was administered in
a post-dilutional fashion.
Connecting CRRT device to ECMO circuit was
performed in the following manner: The inlet (arterial)
line of the CRRT circuit was connected after oxygenator
by a three-way tap and the outlet (venous) line was
connected to the circuit at another tap on infusing can-
nula. The treatment was zero balanced at an ultrafiltra-
tion rate of 20 mL/kg/h. The filters were unchanged
during 24 hours each time.
Determination of inflammation markers
Levels of TNF-α, IL-1β, IL-6 in renal tissues were quan-
tified with enzyme-linked immunosorbent assay kits spe-
cific for the pig cytokines according to manufacturer
instructions (R&D Systems, Munich, Germany). Values
were expressed as picograms per milligram of protein
for tissue samples. The nuclear extracts were prepared
as described elsewhere. Electrophoretic mobility shift assay
was performed with a commercial kit (Gel Shift Assay Sys-
tem; Promega Corporation, Madison, Wis). Nuclear factor
КB (NF-КB) consensus oligonucleotide (AGT-TGA-GGG-
GAC-TTT-CCC-AGG) was labeled with [γ-32P] adenosine
triphosphate (Free Biotech, Beijing, China)with T4
polynucleotide kinase. Equal amounts of nuclear extract
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(60 μg) were added to 9 μL of gel shift binding buffer
(10 mmol/L tris(hydroxymethyl) aminomethane hydro-
chloride, pH 7.5, 50-mmol/L sodium chloride, 0.5 mmol/L
ethylenediaminetetraacetic acid, 1-mmol/L magnesium
chloride, 0.5-mmol/L deoxythymidine triphos-phate,
4% glycerol, 0.05-mg/mL polynucleotide deoxyinosine
deoxy-cytosine) for 15 min at room temperature. The
mixture was incubated for 30 minutes with 1 μL of
the phosphorus 32–labeled oligonucleotide probe. A
1 μL portion of loading buffer was added and the
sample was electrophoresed in a 4% polyacrylamide gel
at 390 V for 1 hour. The dried gel was exposed to x-ray
film (Fuji Hyperfilm; Fuji Photo Film Co, Ltd, Tokyo,
Japan) at 70°C. The intensity of the NF-КB complex
was quantified by densitometry.
Statistical analysis
Measurement data were expressed as mean ± SD. All the
statistical analyses of the data were performed by a com-
mercially available statistical software package (SPSS for
Windows version 13.0; SPSS Inc, Chicago, IL).We used a
repeated measurement analysis of variance (ANOVA with
Repeated Measurements) between C group and S group,
between S group, E group, EC group repeated measure-
ment variables. P ≤0.05 was considered to be significant.
Results
Compared with C group and S group, renal IL-1β ex-
pression in E group increased significantly(p < 0.01) (see
Figure 1). Compared with E group, EC group showed
decreased renal IL-1β expression(p < 0.01).
The expression of renal IL-6 in E group showed sig-
nificant increase as compared with C group and S group
(p < 0.01) (see Figure 2). Compared with E group, EC
group showed renal tissue IL-6 expression decreased sig-
nificantly(p < 0.01).
Compared with C group and S group, E group showed
renal TNF-α expression significant increased(p < 0.01) (see
Figure 3). Compared with E group, EC group showed renal
TNF-α expression decreased significantly(p < 0.01).
Compared with C group and S group, E group showed
renal NF-КB expression increased significantly(p < 0.01)
(see Figure 4). Compared with E group, EC group showed
renal NF-КB expression decreased significantly(p < 0.05).
Figure 1 Renal IL-1β expression in all groups.
Figure 2 Renal IL-6 expression in all groups.
Figure 3 Renal TNF-α expression in all groups.
Figure 4 Renal NF-КB expression in all groups.
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Discussion
This study was designed to elucidate the expression of
renal tissue cytokines by receiving concomitant ECMO
and CRRT in the healthy swine model. Our results
showed that it might remove ECMO-induced cytokines,
maintain the role of immune equilibrium, reduce the ex-
tent of ECMO-related SIRS, thereby leading to improve
ECMO-related acute renal dysfunction.
CRRT was applied to acute renal failure patients have
been widely recognized. CRRT matched with human
kidney by continuously, slowly and convection running.
Its mainly advantage is that it could stabilize the
hemodynamic, improve azotemia, electrolytes and water-
salt metabolism, keep on cleaning cycle of all sorts of cyto-
kines and improve nutrition [10-13].
Previous animal experiments and clinical studies
have shown that blood components are continually
exposed to non-biological artificial surface from car-
diopulmonary bypass pipe and changes of the non-
physiological hemorheology during ECMO running.
This leads to the complement system, the kallikrein
system, neutrophils and vascular endothelial cell acti-
vated, cell surface adhesion molecule expression, mast
cell degranulation, tumor necrosis factor (TNFα),
interleukin (e.g. IL-1β, IL-6, IL-8) and other cytokines
signaling cascad style released,which triggered ECMO-
related SIRS [14-17].
These cytokines amplified the response of neutrophils
and endothelial cells, and which caused extensive micro-
vascular injury, microcirculation acidic metabolites and
a large number of oxygen free radicals which generated
significantly. Anti-inflammatory and pro-inflammatory
cytokines increased, inflammatory response was out of
control and homeostasis of immune system was showed
imbalance in plasma concentrations, These ultimately
lead to multiple organ dysfunction, especially for the
renal dysfunction. NF-КB is a key factor which leads to
inflammation and acute kidney injury and it also can
positively induce the synthesis of a variety of inflamma-
tory cytokines.
The present study showed that inflammatory cytokines
including IL-1β, IL-6, TNF-α, NF-КB significantly in-
creased in the ECMO group, and further confirmed re-
sult that it can be evoked by ECMO-related SIRS when
ECMO treatment used alone. Inflammatory cytokines
including IL-1β, IL-6, TNFα, NF-КB also increased in
the ECMO + CRRT group. However, compared with the
ECMO group, both slowed down significantly. These in-
dicated that the ECMO combined with CRRT treatment
can exert an immunomodulatory effect in order to main-
tain the immune equilibrium. It also can further reduce
the degree of ECMO-related SIRS, and thus play a sig-
nificant role in reversing the occurrence of acute kidney
injury which related with ECMO.
Conclusions
The present data demonstrates that, by receiving con-
comitant extracorporeal membrane oxygenation and
continuous renal replacement therapy could decrease in-
flammatory cytokine. ECMO enables to inflammatory
cytokines including IL-1β, IL-6, TNFα, NF-КB released
significantly, CRRT could also regulate the factors re-
sponsible for inflammation, including decreasing IL-1β,
IL-6, TNF-α-mediated NF-κB pathway. This research
provides a possible explanation to the molecular mech-
anism of improving renal function during combined
ECMO and CRRT. Thus, the widely used combined
ECMO and CRRT can alleviate levels of inflammatory cy-
tokines, maintain immune homeostasis balance and thus
ameliorate the ECMO-related acute kidney injury(AKI).
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